stockrow
Friday 6 November 2026
Export RTSN’s income statement to Excel — free account
Retension Pharmaceuticals, Inc.
RTSN Healthcare Biotechnology
10.58
1.02
−8.79%
Follow RTSN
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | |||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT margin, % | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Net income | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Per share, $ | |||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | — | — | — | |||||
| Earnings | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Cash flow | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Capex | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Book value | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Shares, m | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Valuation, × | |||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Cash, $m | |||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | — | — | — | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Balance, $m | |||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | — | — | — | |||||
| Net debt | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Returns, % | |||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | — | — | — | |||||
| ROIC | — | — | — | — | — | — | — | — | — | — | — | ||||||
| ROE | — | — | — | — | — | — | — | — | — | — | — | ||||||
| People | |||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | 12 | — | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | — | 0.00 | — | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 16 Oct 2026
Retension Pharmaceuticals, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| PMVP PMV Pharmaceuticals, Inc. | $100.1M | — (loss-making) | — | — | n/m | +20.27% (above 0%: growing) | 0.00% | 0.00% | Compare |
| RTSN Retension Pharmaceuticals, Inc. | $96.6M | — | — | — | — | — | — | — | |
| VANI Vivani Medical, Inc. | $96.5M | — (loss-making) | — (loss-making) | −71.87% (below 0%: shrinking) | n/m | +0.39% (above 0%: growing) | 0.00% | 0.00% | Compare |
| MIST Milestone Pharmaceuticals Inc. | $96.2M | — (loss-making) | — (loss-making) | −62.73% (below 0%: shrinking) | n/m | −80.81% (below 0%: shrinking) | 94.28% | (4,584.97%) | Compare |
| VTVT vTv Therapeutics Inc. | $95.0M | — (loss-making) | — (loss-making) | +409,222.22% (above 0%: growing) | n/m | −124.59% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| CBUS Cibus, Inc. | $94.8M | — (loss-making) | — (loss-making) | +6.54% (above 0%: growing) | n/m | +31.62% (above 0%: growing) | 100.00% | (1,300.30%) | Compare |
| ICCC ImmuCell Corporation | $94.2M | 117× | — (loss-making) | +11.50% (above 0%: growing) | +233.33% (above 0%: growing) | +54.86% (above 0%: growing) | 33.92% | 26.93% | Compare |
| SEER Seer, Inc. | $94.1M | — (loss-making) | — (loss-making) | −23.43% (below 0%: shrinking) | n/m | +36.73% (above 0%: growing) | 48.55% | (542.91%) | Compare |
| VXRT VAXART, INC. | $92.4M | 2.8× | — (loss-making) | −85.33% (below 0%: shrinking) | n/m | +117.38% (above 0%: growing) | 100.00% | (162.74%) | Compare |
| Median of peers | $94.9M | — | — | −23.43% | — | +25.94% | 71.42% | (81.37%) |